Tiziana Life Sciences (TLSA) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tiziana Life Sciences (TLSA) has outperformed Upstream Bio (UPB) over the past year, losing 64.3% versus a loss of 93.8%. Upstream Bio is the larger company by market cap ($87.2 million vs $79.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLSA | UPB |
|---|---|---|
| Share price | $0.6206 | $1.59 |
| Market cap | $79.45M | $87.15M |
| 1-day change | -8.14% | -20.50% |
| YTD return | -58.35% | -94.14% |
| 1-year return | -64.33% | -93.78% |
| 5-year return | -52.98% | — |
| EPS (TTM) | $-0.21 | $-3.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.85M |
| Revenue growth (YoY) | — | +20.42% |
| Net income (latest FY) | $-11.86M | $-143.44M |
| Operating margin | — | -5618.82% |
| Net margin | — | -5026.03% |
| 52-week high | $1.90 | $33.68 |
| 52-week low | $0.55 | $1.56 |
| Distance from 52-week high | -67.34% | -95.28% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1203.58% | +1245.91% |
| Average volume | 606.04K | 1.01M |
| Shares outstanding | 128.03M | 54.81M |
| Employees | 10 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSA has outperformed UPB by 29.4 percentage points over the past year.
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
TLSA vs UPB FAQ
Which is bigger, Tiziana Life Sciences or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $87.15M compared with $79.45M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, TLSA or UPB?
TLSA returned -64.33% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Tiziana Life Sciences and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.